Clinical Trials Directory

Trials / Completed

CompletedNCT01729728

Pharmacokinetic, Efficacy and Safety Study of Tapentadol Oral Solution in Children With Postoperative Pain

Open-label Evaluation of the Pharmacokinetic Profile, Safety, and Efficacy of Tapentadol Oral Solution for the Treatment of Post-surgical Pain in Children and Adolescents Aged From 2 Years to Less Than 18 Years.

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
86 (actual)
Sponsor
Grünenthal GmbH · Industry
Sex
All
Age
2 Years – 17 Years
Healthy volunteers
Not accepted

Summary

To find out if a drug called tapentadol administered by mouth safely relieves pain in children. Look at the amount of tapentadol in the blood after a single oral dose. Tapentadol oral solution for children is still being tested and is not yet registered. Tapentadol tablets are effective in treating both acute and chronic pain in adults. This trial will help to understand how tapentadol oral solution works in children.

Detailed description

The lower age limit for the clinical trial was initially set to 3 years of age in the protocol. The trial planned for the inclusion of participants in three age categories. Age 3 to less than 6 years (young children), age 6 to less than 12 years (older children) and age 12 to less than 18 years of age (adolescents). There was a request by the Paediatric Committee (PDCO) at the European Medicines Agency to include participants 2 years of age (very young children). The protocol amendment thus planned to combine the two youngest age groups into a single reporting group. The protocol amendment only planned that the very young children group would have separate analysis for the Faces Pain Scale Revised (FPS-R) Scale and for the presentation of the serum concentrations, because the pharmacokinetic sampling scheme used in the 2 year old participants was different from the young children group (aged 3 to less than 6 years).

Conditions

Interventions

TypeNameDescription
DRUGTapentadolTapentadol oral solution single dose (1mg/kg body weight)

Timeline

Start date
2012-11-01
Primary completion
2014-02-01
Completion
2014-02-01
First posted
2012-11-20
Last updated
2019-11-04
Results posted
2014-11-27

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT01729728. Inclusion in this directory is not an endorsement.